Tivozanib's Safety Will Lead The Way Towards Approva

Aveo Pharmaceuticals' (AVEO) big day is getting closer - on May 2nd, the FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to review the company's lead drug candidate tivozanib for the treatment of advanced renal cell carcinoma (RCC).04/23/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news